

Institute for Pharmacovigilance in Psychiatry, AMSP e.V.

First published: 08/02/2010

Last updated: 11/04/2023

Institution

Hospital/Clinic/Other health care facility

Institution identification

PURI

<https://redirect.ema.europa.eu/resource/46817>

Institution ID

46817

Institution countries

☐ Germany

Type of institution

Hospital/Clinic/Other health care facility

Institution website

<https://www.amsp.de>

ENCePP partner

Yes

Institution description

The AMSP-Institute for Pharmacovigilance in Psychiatry (Arzneimittelsicherheit in der Psychiatrie) is a drug safety program. It assesses severe adverse reactions to all marketed psychotropic drugs in the naturalistic setting of routine clinical treatment of psychiatric inpatients. For AMSP purposes, psychotropic drugs also include neurologic drugs such as anticonvulsants and antiparkinson drugs. > 100 psychiatric hospitals in Germany, Switzerland and Austria have participated in the program from 1993 up to now. Physicians working in the hospitals systematically record severe adverse events, i.e. those that are (potentially) life-threatening or seriously endanger the patient's health, or considerably impair everyday functioning, or require the patient's transfer to another department or ward providing more intensive care. The ongoing project started in 1993.

Institution details

Experience with collecting data directly from individual patients or respondents:

Yes

Interest in carrying out research that is funded by pharmaceutical companies:

Yes

Contact

Stefan Bleich

Main

bleich.stefan@mh-hannover.de

Eckart Ruether

Alternate

eruethe@gwdg.de